The Cliff Gets a Number, and the Number Is Survivable. The Growth Is Not.

Results vs. Consensus

Q4 2025 Scorecard

GAAP diluted EPS of $8.14 includes $0.13 of gains on sales of facilities (primarily an Indiana hospital); adjusted EPS is $8.01. The prior-year adjusted comparative is $6.22, being the $5.63 GAAP figure plus $0.59 of losses on sales of facilities.

The split is the story. HCA beat the earnings line by 8.8% and missed the revenue line by 0.6%, and the reason is visible one row down: revenue per equivalent admission came in $53 below where the Street had it. Consensus had extrapolated Q3's 6.6% same-facility rate growth; the actual print was 2.9%, because the Medicaid supplemental payment net benefit that added roughly $240M year over year in Q3 was approximately flat year over year in Q4.

Year-Over-Year Comparison

The 200bp improvement in total costs and expenses as a percentage of revenue overstates operating progress: 130bps of it is the swing on sales of facilities, from a 1.1% drag in Q4 2024 to a 0.2% benefit in Q4 2025. The clean operating comparison is the 80bp Adjusted EBITDA margin expansion.

Quarter-Over-Quarter Comparison

The sequential table rebuts the year-over-year table in a useful way. Revenue growth decelerated to 1.8% sequentially, yet Adjusted EBITDA grew 6.3% and margin expanded 90bps to 21.1%, the highest of the year. Volume held (same-facility equivalent admissions actually ticked up to 2.5%) while rate collapsed to 2.9%, and the company still expanded margin. That is the cleanest evidence in the release that the cost side is genuinely working, because it happened in a quarter with almost no supplemental-payment help.

Revenue assessment. A 0.6% revenue miss is trivial in isolation and instructive in context. The Street modelled the Q3 rate print forward and was wrong, which is precisely the error our initiation warned against when we wrote that the right adjustment to supplemental payments is to refuse to grow them. Same-facility equivalent admissions of 2.5% with volume holding through a quarter in which management said respiratory had no material year-over-year impact is a genuinely clean volume result. The deceleration in rate to 2.9% is not a deterioration in the business; it is the absence of a one-time benefit.

Margin assessment. Salaries and benefits at 42.8% of revenue extends the trend that anchored our first bull pillar, and contract labor settled at approximately 4.2% of salaries, wages and benefits, which the CFO described as the run rate into 2026. The offsetting concern from last quarter has been quantified rather than resolved: management now expects physician cost growth in the high single digits in 2026. Supplies at 15.3% of revenue rose 80bps sequentially, which bears watching, though the year-over-year ratio is flat.

EPS assessment. The full-year picture is the one that matters here. FY2025 delivered $28.33 of GAAP diluted EPS and $28.21 adjusted, against a guidance range of $27.00 to $28.00 set in October. HCA beat the high end of its own adjusted range by $0.21 and did so while missing the fourth-quarter revenue consensus, which tells you where the earnings leverage sits. It sits in cost control and share count, not in price.

Full Year 2025 in Review

Two disclosures on the call reframe the year. First, the full-year net benefit from Medicaid supplemental payments increased $420M, not the $250M to $350M management guided to in October. The difference is the Virginia retro payment received in Q4, which management explicitly identified as the one item that landed differently than the October guide contemplated. Second, hurricane-affected markets contributed approximately $125M of Adjusted EBITDA growth for the year, against the roughly $100M target, with about $150M of that arriving in Q4 alone. Both of the soft assumptions we flagged in our initiation resolved favorably.

Assessment: Netting those out, roughly $545M of the $1,684M year-over-year Adjusted EBITDA increase, or 32%, came from supplemental payments and hurricane-market recovery combined. That is a lower policy-and-comparison dependency than the 40%-plus we calculated for Q3 in isolation, and it means the full-year operating story is stronger than the third quarter made it look. It also means both tailwinds are now largely spent, which is exactly what the 2026 guide reflects.

Volume, Pricing and Payer Mix

Reported vs. Same-Facility Operating Statistics

Assessment: Inpatient revenue per admission grew only 0.6% year over year, against 6.3% in Q3. That single line is where the supplemental-payment reversal shows up most starkly, because supplemental payments attach disproportionately to inpatient Medicaid volume. Meanwhile inpatient surgery cases were flat on a same-facility basis and outpatient surgery declined 0.5%, a deceleration from Q3's +1.4% and +1.1%. Surgical softness alongside admissions growth of 2.4% means the volume mix skewed toward medical admissions, which management corroborated by describing rising acuity in the medical book.

Payer Mix (same-facility equivalent admissions, YoY)

Management attributed both the exchange deceleration and the Medicaid improvement to the same cause: the Medicaid redetermination process in the prior-year period has now fully sunsetted, which flattered exchange comparisons through 2025 and depressed Medicaid ones. With that distortion gone, the underlying picture is a commercial book growing about 1% and a government book growing 2% to 3.5%.

"The health care exchanges, you know, clearly, we did not see a pull forward of demand as people were anticipating premium increases." — Mike Marks, CFO

Assessment: That sentence closes an open question from our initiation, where we noted that management had declined to say whether Q4 elective scheduling showed patients accelerating procedures ahead of coverage loss. The answer is no. The absence of a pull-forward is mildly good news for the 2026 comparison, since nothing was borrowed from it, and mildly bad news for the interpretation of Q4 volumes, since none of the 2.5% came from panic demand. More concerning is total commercial at 1.1%. The highest-margin category is now growing at a third of Q3's rate, before the subsidy expiration has had any effect at all.

Outpatient: Growing Revenue on Flat Cases

Outpatient revenue as a percentage of patient revenue reached 39.7%, and management said outpatient revenue grew faster than inpatient revenue in the quarter despite same-facility outpatient surgical cases declining 0.5%, with hospital-based roughly flat and ambulatory surgery centers down about 1.5%. The company frames outpatient across four categories: emergency services, outpatient surgery (hospital-based and ASC), ambulatory platforms (physician clinics and urgent care), and other hospital-based outpatient services. All four grew revenue.

"Payer mix, though, continued to be soft with declines to prior year primarily driven by Medicaid. In addition to the payer mix environment, we saw a decline in lowering intensity cases like ENT. As a result, we had good growth in net revenue and earnings in our outpatient surgery overall, inclusive of both the hospitals and the ambulatory surgery center platform." — Mike Marks, CFO

HCA added roughly 100 business units to its outpatient footprint during 2025, bringing the total to approximately 2,700 facilities, against a stated target of 18 to 20 outpatient facilities per hospital by the end of the decade.

Assessment: Growing outpatient revenue and earnings on declining case volume is mix improvement, and shedding low-intensity ENT cases while retaining higher-acuity work is the right trade. But it is worth being precise about what this is: HCA is getting more revenue per outpatient case, not more outpatient cases. The 100 new business units added in 2025 did not produce case growth, which suggests either a ramp lag or a market where the incremental site of care is competing for a static pool of procedures.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Markedly more forthcoming than last quarter, and structured around pre-empting the bear case rather than deferring it. Management arrived with the exchange exposure sized, the mitigation quantified, the supplemental-payment decline decomposed into thirds, and a new buyback authorization already board-approved, which reads as a deliberate decision to convert an open-ended policy fear into a bounded arithmetic problem. The confidence was strongest on cost execution and weakest, appropriately, on the behavioral assumptions inside the exchange model, which management repeatedly labelled as judgments to be tested against experience.

1. The Exchange Exposure, Finally Sized

The disclosure we identified last quarter as the most consequential omission in the release arrived in the CFO's answer to the second question of the call. Exchange volumes were approximately 8% of admissions and 10% of revenue in 2025. With that denominator, the exposure becomes modellable for the first time.

"as a reminder, our health exchange volumes represent approximately 8% of admissions and 10% of revenue in 2025." — Mike Marks, CFO

The guidance impact is a $600M to $900M adverse effect on Adjusted EBITDA, encompassing administrative reforms enacted in 2025, the One Big Beautiful Bill Act, and the expiration of the enhanced premium tax credits. The model behind it assumes a 15% to 20% decline in exchange volumes, of which roughly 15% to 20% migrate to employer-sponsored coverage (which carries a benefit) and the remainder to uninsured status, with a further utilization decline for that group.

Assessment: Sizing the exposure is worth more to the investment case than the size itself. A $600M to $900M hit against $15.566B of 2025 Adjusted EBITDA is 3.9% to 5.8%, roughly half of which is offset by the resiliency program. That is absorbable, and the market's 7.1% move says it was better than positioning implied. The residual risk is no longer the magnitude of the disclosed range but whether the behavioural assumptions inside it hold, and those are the company's own estimates of how displaced patients behave, tested against nothing yet.

2. The 2026 Bridge: Flat Net Income, and a Smaller Share Count

The guidance table is where the year's real message sits. Revenue of $76.500B to $80.000B, Adjusted EBITDA of $15.550B to $16.450B, net income attributable to HCA of $6.495B to $7.035B, and diluted EPS of $29.10 to $31.50 on a guided share count of 223.5 million.

At the midpoint, guided net income of $6.765B compares with $6.784B delivered in 2025. That is a 0.3% decline. Guided Adjusted EBITDA of $16.000B against $15.566B is growth of 2.8%. Guided EPS of $30.30 against $28.33 is growth of 7.0%. The reconciliation between flat net income and 7% EPS growth is a share count guided 6.7% lower.

Assessment: This is the single most important fact in the release and it went largely unremarked in the reaction. HCA is guiding to a year of no earnings growth in absolute dollars, in which every dollar of per-share progress is manufactured by retiring stock. The buyback is rational and well-funded, and at a reasonable multiple it creates real value. But an investor paying 16.7x for 7% EPS growth should understand they are paying for capital allocation, not for the business growing, and that the arithmetic works only for as long as the multiple stays low enough to make repurchase accretive.

3. Resiliency: $400M, and Now a Number Instead of a Posture

Last quarter management reframed the $600M to $800M resiliency target as an open-ended program and declined to give cumulative progress. This quarter it produced a specific, guidance-embedded figure: approximately $400M of incremental savings in 2026 versus 2025, sized off an assessment of implementation status across the opportunity list.

"our program has four key areas of focus: revenue integrity, variable and fixed cost efficiencies, and capacity management. We are leveraging three primary capabilities in driving our financial program. First, internal and external benchmarking and advanced analytics. Second, digital transformation with AI and automation. And third, expanding and leveraging our shared service platforms." — Mike Marks, CFO

The CEO characterised the program's timing relative to the subsidy expiration as fortunate rather than reactive.

"that's why the program is lining up in a well-timed manner with some of the enhanced premium tax credit challenges but we see this program continuing to mature. And as we get more capable at using these tools, it's gonna help us find even more opportunities. But this is not a one-time event." — Samuel Hazen, CEO

Assessment: Putting $400M inside guidance is a meaningfully stronger commitment than last quarter's pipeline language, because a miss now shows up in the numbers rather than in a narrative. It converts our third bear-adjacent concern about resiliency accountability into something testable across 2026. Still absent: any cumulative figure against the original $600M to $800M target, which remains unreconciled two years on.

4. Supplemental Payments Decompose Into Thirds

Guidance assumes a $250M to $450M decline in net benefit from supplemental payment programs. Management broke that into three roughly equal components, and named the Texas program that was paused.

"So the pause program is called Atlas. Stands for aligning technology by linking interop systems. There was a commissioner that issued a termination notice on that program on their way out as they were leaving office. The new executive commissioner that has is now in place has agreed to review that program, effectively putting it on pause versus terminate." — Mike Marks, CFO

The other two thirds are the non-recurrence of the Virginia retro payment received in Q4 2025, and Tennessee reverting to four quarters of net benefit in 2026 after six quarters in 2025. Guidance excludes any impact from additional grandfathered-application approvals, which management again declined to size.

Assessment: Two of the three drivers are pure arithmetic (a one-time payment not recurring, and a six-quarter year normalising to four) and therefore highly reliable. The third, the Texas Atlas pause, is a genuine binary with a plausible path back, since a departing commissioner's termination notice was converted to a review by their successor. That makes roughly $85M to $150M of the guided decline potentially recoverable within the year, on top of the excluded pending approvals. The supplemental-payment line, which was a source of upside surprise through 2025, is now a source of guided-in decline with unguided upside attached.

5. Where the Displaced Patients Go

The most analytically useful exchange on the call concerned patient behaviour after coverage loss, and management supplied a utilization assumption that had not previously been public.

"for the ones that go to uninsured, we do anticipate a decline in utilization from those individuals no longer having coverage. And we believe that that decline is somewhere in the 30% range. Compared to their utilization of health care services when they had health care insurance through the exchange." — Mike Marks, CFO

Management added that the exchange population uses the emergency room more heavily than the traditional managed care or commercial population, and that displaced patients would therefore concentrate in emergency settings.

Assessment: The 30% utilization-decline assumption is the load-bearing estimate in the entire 2026 guide, and it cuts both ways. A larger decline reduces volume but also reduces uncompensated care; a smaller decline preserves volume that arrives at negative contribution margin through the emergency room. The concentration in emergency departments is the genuinely unattractive detail, because emergency volume is the least schedulable, least profitable and most cost-inelastic care HCA delivers.

6. Uncompensated Care and the Metal-Tier Question

Asked what guidance assumes for bad debt and uncompensated care, management described two distinct effects: growth in uninsured presentations, which reserve immediately, and a possible shift within retained exchange coverage from silver to bronze plans, which raises patient-due balances and lowers collection rates.

"when someone without insurance comes into the hospital, you largely those patients are reserved right away. Right? So that growth kind of immediately transitions into a comp safe care. The other component that we're studying carefully is the amount that patients owe when they do have insurance." — Mike Marks, CFO

Management's judgment is that the larger 2026 effect is the growth in uninsured volume rather than the collectability deterioration from a silver-to-bronze migration.

Assessment: The ranking is credible and the second-order risk is understated. A silver-to-bronze migration affects patients who keep coverage, so it is not captured in the 15% to 20% volume-decline assumption at all; it degrades the economics of the retained book. Management is studying it rather than sizing it. If the exchange population that stays insured trades down in metal tier at scale, the revenue-per-exchange-admission assumption inside the $600M to $900M range is too generous, and that is a channel the guide does not visibly bound.

7. Capital Allocation: A $10B Authorization and an 8.3% Dividend Raise

The board authorised a new $10B repurchase program on top of the $750M remaining at year-end, and raised the quarterly dividend to $0.78 from $0.72. Management said it anticipates completing a majority of the existing authorization during 2026. HCA retired $10B of stock in 2025 and paid $679M of dividends, against $12.636B of operating cash flow and $4.9B of capital expenditure.

Assessment: The authorization is the mechanism that makes the EPS guide credible, and its timing alongside a flat-net-income year is not coincidental. At the current market value the new authorization represents close to 9% of shares outstanding. The concern raised in our initiation, that HCA might lean harder into buyback precisely when earnings compress, is now the stated plan. It is defensible at 16.7x and would be less so higher. Worth noting that total debt rose to $46.492B from $44.511B at September 30, so a portion of the repurchase is being funded with balance sheet capacity rather than free cash flow, though leverage remains at the low end of the target range.

8. Capital Spending Raised on a $7B Approved Pipeline

Capital expenditure guidance rose to $5.0B to $5.5B for 2026 from the roughly $5.0B spent in 2025 (actual: $4.9B). The CEO grounded the increase in an approved-project pipeline he described as an all-time high.

"I think our capital is at an all-time high for approved projects that will come online in '26, '27, maybe early '28. It's almost $7 billion of capital that's in the pipeline." — Samuel Hazen, CEO

Hospitals are running 73% to 74% occupancy, and the CEO said the outpatient acquisition pipeline is better than it has been in several years, while noting no attractive opportunities have emerged among tax-exempt hospital systems despite balance-sheet capacity.

Assessment: Raising capital spending into a flat-earnings year is a confident signal and a real use of cash that competes with the buyback. Occupancy in the low 70s is high enough to justify capacity addition without being so high that it constrains near-term volume. The absence of hospital M&A opportunity is notable given the widely held expectation that subsidy expiration would distress smaller non-profit operators and create acquisition targets. That thesis has not materialized yet, which is a mild negative for the long-term consolidation case.

9. The Rural Health Transformation Program: Unguided Optionality

The One Big Beautiful Bill Act's Rural Health Transformation Program has allocated funding to all 50 states, but management said program details, timing, structure and award sizes remain undisclosed, and it is not reflected in guidance. The CEO said roughly 15% of HCA hospitals are rural in some form, and pointed to telemedicine, transport, satellite clinics and graduate medical education as additional avenues for participation across roughly 20 different state programs.

Assessment: A second unguided upside channel alongside the pending grandfathered applications. Neither is quantified and neither should be modelled, but their existence means the 2026 guide has more identified upside optionality than downside beyond the disclosed ranges. That asymmetry is worth something and is part of why the stock rallied.

10. Payer Digital Engagement and Working Capital

HCA has launched engagements with major payers focused on electronic data exchange, administrative simplification and dispute resolution. Management connected this directly to a reduction in net days in accounts receivable, particularly in the fourth quarter.

"we had a nice reduction in net days in AR, especially in the fourth quarter. That really reflects the benefits of sharing data and exchanging data to payers digitally and certainly is a part of what's driving those enhancements." — Mike Marks, CFO

Assessment: This is the constructive counterpart to the adversarial denials-and-disputes dynamic we flagged in our initiation. HCA appears to be pursuing both tracks simultaneously: AI-assisted denial defence on one side, collaborative data integration on the other. The working-capital evidence is real and shows up in the 20% full-year operating cash flow growth. It is also the least policy-exposed source of incremental cash in the story.

11. The Technology Agenda and an EHR Transition

The CEO laid out a three-domain technology framework: administrative (revenue cycle, HR, IT, supply chain), operational (throughput, asset productivity, scheduling, staffing), and clinical, which he called "the holy grail." Underneath it is an electronic health record migration from one system to another, being accelerated to standardize datasets that have historically varied by hospital.

"We're investing in our electronic health record transition from one system to another, and we're accelerating into that platform. That a very important foundational piece for our company and that we're gonna be able to standardize datasets across all of our hospitals." — Samuel Hazen, CEO

Assessment: An enterprise-wide EHR migration across 190 hospitals is a large, disruptive, multi-year undertaking with a well-documented industry history of productivity dips during conversion. Management framed it entirely as an enabler and did not discuss transition risk, cost, or timeline. Some of the 2026 resiliency savings are explicitly attributed to administrative-domain AI that depends on this data standardization, which links a cost commitment to a project whose schedule was not disclosed.

Guidance & Outlook

The 2026 Adjusted EBITDA Bridge

Working the bridge backwards is instructive. Taking the midpoints, $16.000B of guided Adjusted EBITDA less $15.566B delivered is $434M of growth. Adding back the guided headwinds ($750M exchange midpoint plus $350M supplemental midpoint, or $1,100M) and subtracting the $400M resiliency offset implies core operational growth of roughly $1,134M, or about 7.3% on the 2025 base, before any policy effect.

Street at. No pre-print FY2026 consensus was published in a form we can cite, so the guide is best assessed against the reaction: the stock rose 7.1%, which says the disclosed exchange range came in at or below what positioning implied. Quantitative ranking systems carried HCA at a sell-equivalent rating into the print, and the shares had drifted 1.0% lower over the prior thirty days, so the setup was not crowded.

Guidance style. Consistent with the pattern established last quarter, the guide embeds every identified headwind at full weight while excluding both identified upside channels. HCA beat the high end of its own FY2025 adjusted EPS range, and its FY2025 supplemental-payment benefit came in $70M to $170M above the October guide because of an item it had explicitly excluded. The same structure is present in the 2026 guide.

Implied quarterly shape. The exchange headwind builds through the year as coverage lapses and utilization adjusts, while the resiliency savings ramp with implementation. Management said it would test its assumptions against actual experience at the end of the first and second quarters. That points to a back-half-weighted year and makes Q1 2026 a low-information quarter for the central debate, with the added complication that a significant winter storm was affecting Nashville and several markets as the call took place.

Analyst Q&A Highlights

What the Guidance Assumes on Each Expense Line

The opening question sought the cost-side assumptions behind the margin guide. Management confirmed stable margins, stable labor and contract labor at its current run rate, then volunteered the one line expected to run hot, quantifying physician cost growth for the first time.

Q: "I wondered maybe because the focus is on the top line, of course, in your comments, can you talk about the expense items SWB, supplies, other operating expenses, professional fees, etcetera. What are your underlying assumptions there that are embedded in the guidance? Is there margin improvement opportunities on any of those lines in '26?"
— A.J. Rice, UBS

A: "the midpoint of our revenue and adjusted EBITDA guidance range suggest expectations for pretty stable margins in 2026 compared to 2025. As we noted on our third quarter call, we continue to assess mostly stable trends in our operating costs consistent with the last couple of years. I might note that we do see and would expect continued physician cost pressures and believe that those could even be maybe in the high single digits of growth in '26 versus '25."
— Mike Marks, CFO

Assessment: High-single-digit physician cost growth guided into 2026 follows 11% in Q3 2025. Two consecutive years of well-above-inflation growth in a line worth roughly a quarter of other operating expenses is now a structural feature, not a transient one. It is also, notably, the only cost line where management guided to deterioration, which lends credibility to the "mostly stable" characterization of the rest.

Sizing the Resiliency Program Against the Subsidy Headwind

The follow-up sought detail on the $400M offset and the timing of volume loss. The answer laid out the resiliency architecture and then, unprompted within the same response, delivered the exchange-exposure disclosure that had been withheld for two quarters.

Q: "So it sounds like the net negative headwind from ACA subsidies is in the $200 to $500 million range. Can you just go into more of the resiliency programs, provide some more detail on what's up that $400 million and obviously, the confidence and executing throughout the year just from a timing perspective and when you expect to lose potential volume?"
— Ann Hynes, Mizuho

A: "Our model contemplates a 15% to 20% decline in our Hicks volumes for 2026. We assume this volume will migrate to either employee sponsored insurance or to uninsured. Of the decline in our HICS volumes, we assume approximately 15% to 20% will move to employee sponsored coverage, which carries a benefit with the remaining migrating to uninsured which includes a decline in utilization from those individuals no longer having coverage."
— Mike Marks, CFO

Assessment: The questioner's framing (a $200M to $500M net headwind) nets the exchange hit against resiliency, and management did not correct it, which is a tacit confirmation that the $400M offset should be applied against the $600M to $900M gross figure. That leaves a net policy drag of roughly $200M to $500M against $15.566B, or 1.3% to 3.2% of Adjusted EBITDA. Framed that way, the subsidy cliff that dominated the story for two quarters is a rounding error on the earnings base. The volume story is a different matter.

Whether Core Growth Is Running Above the Long-Term Algorithm

A pointed attempt to back into the underlying growth rate by stripping the disclosed swing factors out of both years. Management declined to endorse a specific core number while confirming each component of the bridge.

Q: "just are there any one-timers you should be adjusting out for 2025? But if you take the baseline of '25 and pull out I think, $450 million to $900 million from Hicks as supplemental payments, offset by the resiliency programs wanna make sure that I'm calculating the core growth of what each is doing at sort of 3% to 12% the 7% of the midpoint versus just your long-term guidance of four to 6%. So you're still guiding core above your long-term guidance?"
— Pito Chickering, Deutsche Bank

A: "I think from a range perspective, that I would just reiterate two or three of the moving parts for clarity. You know, we've noted the range of potential adverse impact from the exchanges of $600 million to $900 million. We've noted that we believe that the supplemental payments could have a $250 million to $450 million decline in net benefit... So I think in taking those kind of swing factors into account, Pito, we do agree."
— Mike Marks, CFO

Assessment: "We do agree" is management endorsing, without restating, that core growth embedded in the guide runs above the long-term 4% to 6% algorithm. Our own bridge arithmetic lands at roughly 7.3% core Adjusted EBITDA growth at the midpoint, consistent with the questioner's construction. That is a genuinely strong underlying business being masked by policy drag, and it is the strongest argument the bulls have.

How the Exchange Reforms Flow Through the Volume Outlook

A request to locate the exchange drag inside the 2% to 3% volume range, and to understand the utilization assumption for those losing coverage. The answer produced the 30% utilization-decline estimate and the emergency-room concentration point.

Q: "Can you give us a sense for how the exchange reforms and the subsidy expirations will impact the volume outlook? I'm curious if there's a drag that's being absorbed within the 2% to 3% volume outlook from the exchange, expiration. And can you also give us a sense for how you're thinking about the decline in utilization from folks that moved to uninsured within your outlook?"
— Matthew Gillmor, KeyBanc

A: "yes, I do think that the overall volume of the company, although it's within that range of 2% to 3%, has an impact here on exchanges... The only other thing I might mention with the exchange population is we find that they tend to utilize the emergency room in a way that's heavier than our traditional managed care or commercial population."
— Mike Marks, CFO

Assessment: Confirming the exchange drag sits inside the 2% to 3% range rather than outside it means the non-exchange business must grow faster than the headline to compensate. With total commercial excluding exchanges growing about 1% in Q4, that burden falls on Medicare and Medicaid, which grew 3.5% and 2.2%. The volume guide is therefore a government-payer growth story, and government payers carry lower rates than the commercial book being lost.

What the Texas Program Pause Actually Is

The most specific question on the supplemental-payment decline drew the most specific answer of the call, including the program's name, the circumstances of its suspension, and its share of the guided decline.

Q: "Could you expand a little bit on the pause Texas Medicaid supplemental payment that was mentioned during the guidance color. I guess, what exactly is happening there? And what needs to happen for that payment to come back online in 2026? And how much, I guess, of the year-over-year impact is that driving?"
— Steve Baxter, Wells Fargo

A: "There was a commissioner that issued a termination notice on that program on their way out as they were leaving office. The new executive commissioner that has is now in place has agreed to review that program, effectively putting it on pause versus terminate. We don't know yet the timeline for this review... This Texas pause is about a third of that decline."
— Mike Marks, CFO

Assessment: A departing official's termination notice converted into a review by their successor is about as recoverable as a policy setback gets. Roughly $85M to $150M of guided Adjusted EBITDA decline hinges on a Texas administrative decision with no disclosed timeline. It belongs in the upside column alongside the pending grandfathered approvals, and it is the reason the low end of the supplemental-decline range deserves more weight than the midpoint.

Whether Payer Mix Normalization Persists

A question on Medicaid inflecting positive for the first time in 2025 produced the explanation that ties the exchange deceleration and the Medicaid improvement to a single cause, and the confirmation that no demand pull-forward occurred.

Q: "I just wanted to double click on the payer mix and if you can share any color on how it played out. Compared to your internal expectations, specifically Medicaid inflecting positively for the first time in 2025, and if that's something you expect to persist?"
— Sarah James, Cantor Fitzgerald

A: "this also impacted Medicaid, is just the timing of the Medicaid redetermination process in the prior year. So we think we have fully sunsetted that timeline in prior year. And so you saw you know, less exchange growth, and you also saw a bit more Medicaid volume. And Medicaid is 2.2% growth over prior year. Know, seems to be now back to kind of a normal growth rate."
— Mike Marks, CFO

Assessment: This reframes the entire 2025 payer-mix narrative. The 8% exchange growth that looked like structural share gain in Q3 was substantially a redetermination-timing comparison, and it decayed to 2.5% once that comparison lapsed. Anyone who built an exchange-driven growth case off the Q3 disclosure was building on a base effect. It also means the 2026 exchange decline starts from a lower and more honest run rate than the Q3 print implied.

Whether Subsidy Expiration Creates Acquisition Opportunity

A question testing the widely held view that smaller operators would be distressed into selling. The CEO's answer was a clear no, and redirected to organic deployment.

Q: "maybe fair to expect smaller hospitals and health systems, seeing more detrimental impact from subsidy expiration and impacts from the one BBB. I guess now that subsidies are expired, can you give us a sense on your M and A opportunities, if that pipeline is bigger, smaller, size of the assets?"
— Ryan Langston, TD Cowen

A: "With respect to hospitals and tax-exempt hospitals, specifically, you know, we just haven't seen it yet. That there is a significant opportunity for the company that makes sense from a financial standpoint... The opportunities to invest in those markets organically is compelling."
— Samuel Hazen, CEO

Assessment: A candid negative on a popular thesis. The consolidation-through-distress case has been part of the bull argument for hospital scale operators for years, and HCA is saying that even after subsidy expiration it sees nothing worth buying at a sensible price. That pushes the growth burden entirely onto organic capital deployment, where the company does have a nearly $7B approved pipeline, and removes an optionality leg some investors were carrying for free.

What They're NOT Saying

1. What happens to the exchange book in 2027 and beyond. The $600M to $900M range is a 2026 estimate that assumes a 15% to 20% volume decline. If attrition continues into a second year, or if the retained population trades down further in metal tier, there is a second-year effect nobody has framed. Guidance stops at December 2026.
2. Cumulative progress against the original $600M to $800M resiliency target. Asked in Q3, not answered. Not addressed at all this quarter, despite management producing a precise $400M figure for 2026 alone. The 2023 target remains unreconciled.
3. The EHR migration's cost, timeline and disruption risk. A multi-year enterprise conversion across 190 hospitals was described purely as a strategic enabler. No capital figure, no schedule, no acknowledgement of the productivity dip that typically accompanies such conversions, and some 2026 resiliency savings depend on the data standardization it delivers.
4. The metal-tier migration's quantified effect. Management identified silver-to-bronze migration as a real risk to patient-balance collectability, described it as being studied, and gave no range. It affects the retained exchange population, so it is not inside the volume-decline assumption.
5. Q4 self-pay volume. Q3 disclosed self-pay equivalent admissions down 6%, a favourable datapoint management highlighted. Q4's payer-mix walk covered commercial, exchanges, Medicare and Medicaid, and omitted self-pay entirely. In the quarter immediately preceding a guided increase in uninsured volume, the omission is conspicuous.
6. Where the debt is going. Total debt rose roughly $2.0B sequentially to $46.492B while $2.6B of stock was repurchased. Management characterised leverage as at the low end of the target range and did not address the extent to which buybacks are debt-funded.
7. The winter storm's impact on Q1. Asked about a significant storm affecting Nashville and other markets during the call, the CEO said the company did not yet know the impact. Fair, but it means the first quarter carries an unquantified weather variable on top of the exchange transition.

Market Reaction

• Pre-print setup: HCA closed at $472.38 on January 26, up 1.2% year to date against the S&P 500 at +1.5%, up 42.3% over trailing twelve months but down 1.0% over the trailing thirty days. The 52-week closing range entering the print was $306.30 to $515.85. The stock was consolidating below its highs after a very strong 2025, and carried a sell-equivalent quantitative rank.
• Reaction session (January 27, before-open reporter): Opened at $505.00, a 6.9% gap up, traded $496.01 to $527.55 (+5.0% to +11.7% versus the prior close), and closed at $505.84, up 7.1% or $33.46. The S&P 500 rose 0.4% the same session.
• Volume: 3.1 million shares against a 30-day average of 1.1 million, or 2.8x normal.

The reaction is more informative than the quarter. HCA missed the revenue consensus and guided to flat net income, and the stock added 7.1%. That is a positioning outcome, not an estimate-revision outcome. The market had been discounting an unquantified subsidy cliff for two quarters, and the number, once disclosed and net of the resiliency offset, resolved to a low-single-digit percentage of Adjusted EBITDA. Relief, plus a fresh $10 billion repurchase authorization landing on the same morning, explains the move.

The intraday pattern supports that reading. The stock gapped 6.9% at the open, before the call began, on the press release alone, and then traded as high as $527.55 during the call before settling essentially at the opening level. The market made its decision on the guidance table and the buyback authorization, and the two hours of detail on utilization assumptions and metal-tier migration moved it not at all. That is a market pricing the resolution of uncertainty rather than the content of the resolution.

Street Perspective

Debate: Is Flat Guided Net Income a Trough or a New Normal?

Bull view: 2026 is a policy-absorption year, not a deterioration. Core operational growth embedded in the guide runs above 7% at the midpoint, ahead of the company's own 4% to 6% long-term algorithm. Strip the one-year exchange and supplemental drag and the earnings power is intact and compounding; 2027 laps the reset with the resiliency program still ramping.

Bear view: "Core growth ex-headwinds" is the oldest framing in equity research and the headwinds keep arriving. The OBBBA Medicaid provisions bite from 2028, exchange attrition may extend into a second year, and physician costs are guided to high single digits. A company that needs a 6.7% share-count reduction to show 7% EPS growth is not absorbing a one-year event.

Our take: The bull framing is arithmetically correct and the bear framing is directionally right about the pattern. What settles it for us is that the operating evidence in Q4 was genuinely strong on a clean comparison: 90bps of sequential margin expansion in a quarter with no supplemental-payment help. The business is compounding. The problem is not the trough; it is that the market is paying a re-rated multiple for a year in which the compounding will not be visible in reported net income.

Debate: Is the $600M to $900M Exchange Estimate Credible?

Bull view: Management built it from proprietary volume data plus external studies, disclosed the underlying assumptions in unusual detail (15% to 20% volume decline, 15% to 20% of that to employer coverage, roughly 30% utilization decline for the newly uninsured), and set a range wide enough to accommodate error. The transparency is itself evidence of rigour.

Bear view: Every input is a behavioural judgment about how people respond to losing coverage, tested against no observed data, and management said so repeatedly. The estimate excludes metal-tier migration effects on the retained book. Displaced patients concentrate in emergency departments, the least profitable setting, so the revenue decline understates the margin decline.

Our take: The range is honestly constructed and probably too narrow in its coverage rather than its width. The specific gap is the retained population: a silver-to-bronze shift degrades economics for patients who never appear in the 15% to 20% attrition figure, and management flagged it without bounding it. Expect the disclosed range to hold on volume and to be tested on collectability, with the first real evidence arriving with Q1 results.

Debate: Does 16.7x Make Sense for This Algorithm?

Bull view: HCA just compounded adjusted EPS 28.5% in 2025, beat the high end of its own range, generated $12.636B of operating cash flow, holds leverage at the low end of target, and has a $10B authorization plus two unguided upside channels (pending CMS approvals and the Rural Health Transformation Program). Paying 16.7x for that franchise through one policy-reset year is reasonable.

Bear view: 16.7x sits at the upper end of where this stock has historically traded, and it is being paid for a guide with zero net income growth in which all per-share progress is buyback-funded, partly with incremental debt. The multiple expanded on the news; the earnings did not.

Our take: Both descriptions are accurate, which is the definition of a fairly valued stock. Our initiation argued the risk/reward was balanced at $447 with the cliff unquantified. The cliff is now quantified and smaller than feared, which is worth something, but the price rose 13% in the interim and captured it. We would want either a lower multiple or visible evidence that the exchange attrition is landing at the favourable end of the range before paying up.

Model Update Needed

Valuation framework. At the January 27 close of $505.84, HCA trades at 16.7x the midpoint of guided 2026 diluted EPS of $29.10 to $31.50, and at roughly 7.1x guided Adjusted EBITDA of $16.000B on an enterprise value that includes $46.492B of debt. The multiple sits at the upper end of where this business has historically traded and is being applied to a year of guided-flat net income. Applying 15.5x to 17.5x to the $30.30 midpoint yields a fair value band of roughly $470 to $530, midpoint about $500, implying roughly -1% from the current price. We skew our own estimate modestly above the guide midpoint on the recoverable Texas program and the two excluded upside channels, but not enough to change the conclusion: the stock is priced for the outcome management has guided to.

Thesis Scorecard Post-Earnings

Overall: Thesis strengthened on operations, unchanged on valuation. Bull #1 is now the most robust pillar in the coverage, having been demonstrated in a quarter stripped of policy help. Bull #2 downgrades to Neutral on commercial-mix deceleration. Bear #1 moves from an unquantified threat to a bounded, absorbable one, which is a genuine improvement in the risk profile. A fourth bear point is added to capture the share-count dependency that the 2026 guide makes explicit.

Action: Hold. The reason for our initiation Hold has changed but the conclusion has not. In October the stock was fairly valued because the largest variable was unquantified; today it is fairly valued because the variable has been quantified favourably and the price has already moved to reflect it. The entry point we wanted in the low $400s never arrived. We would revisit constructively on any pullback toward the mid $400s, or on Q1 evidence that exchange attrition is tracking at the low end of the 15% to 20% assumption. The Q1 print in late April is the first real test of the model, though management has cautioned that the assumptions will not be fully testable until mid-year.